IMVARIA Secures Strategic Investments for AI-Driven Lung Diagnostics
January 14, 2026, 4:09 am
Location: United States, Maryland, Bethesda
Employees: 10001+
Founded date: 1887
IMVARIA, a Berkeley health tech innovator, secured strategic funding. New capital expands its AI-driven diagnostic services for lung diseases. InHealth Ventures led the round. Labcorp Venture Fund and Cedar Crest Holdings participated. IMVARIA's platform, including FDA-authorized Fibresolve, transforms early disease detection. It offers non-invasive AI tests for pulmonologists. The company aims to enhance patient care and streamline clinical workflows with advanced machine learning. A recent NIH grant fuels further development for chest CT malignancy assessment. This investment accelerates AI's role in critical medical diagnostics.
IMVARIA, a prominent Berkeley, CA-based health tech company, has secured significant strategic investments. This funding will accelerate the expansion of its cutting-edge AI-driven diagnostic services. The capital injection targets various forms of lung disease. It ensures greater accessibility for clinicians, particularly pulmonologists. This move solidifies IMVARIA's position in the evolving digital health landscape.
The investment round saw InHealth Ventures take the lead. This early-stage fund is closely associated with InHealth Group, a leader in screening and diagnostics. Additional participation came from the Labcorp Venture Fund. Existing partner Cedar Crest Holdings also reinvested. Financial terms of the deal remain undisclosed. This strategic backing underscores confidence in IMVARIA's innovative approach to healthcare.
IMVARIA develops sophisticated AI-driven digital biomarker solutions. These tools empower clinicians. They facilitate earlier and more precise diagnoses and prognoses. The company’s AI platform leverages automated, machine-learning algorithm technology. It transforms complex clinical decision-making into data-driven science. This approach promises a paradigm shift in medical diagnostics.
The company's primary focus remains lung disease. This area presents significant diagnostic challenges. IMVARIA’s AI platform offers a new pathway for non-invasive diagnoses. It targets conditions like interstitial lung disease, including idiopathic pulmonary fibrosis. Early detection is critical for better patient outcomes. IMVARIA's technology aims to provide this crucial advantage.
Fibresolve stands as IMVARIA's flagship offering. This AI-powered test received FDA authorization in early 2024. Its use is authorized for suspected interstitial lung disease. Fibresolve employs a centralized model. It applies artificial intelligence to guide non-invasive diagnoses. The service integrates smoothly into existing clinical workflows. It minimizes the burden on healthcare providers.
Fibresolve also holds the esteemed FDA Breakthrough Device designation. This status highlights its potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases. Furthermore, the American Medical Association (AMA) has adopted CPT billing codes for Fibresolve. These codes simplify clinical ordering and reimbursement processes. They remove significant barriers to widespread adoption.
IMVARIA's commitment to innovation extends beyond existing solutions. The company recently secured a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). This grant supports the development of a new test. This test aims to improve malignancy assessment in chest CT scans. It builds upon IMVARIA’s robust existing lung disease platform. This expansion promises new capabilities in cancer detection.
The company was founded in 2019. Its founders are practicing physicians. They trained at Stanford School of Medicine. They also bring engineering expertise from Google. This unique blend of medical insight and technological prowess underpins IMVARIA's success. It has enabled the development of AI-powered tests with two FDA authorizations. This background fosters a deep understanding of clinical needs.
IMVARIA has established commercial traction. Its approach integrates AI seamlessly into clinical settings. The goal is to provide richer data sets for clinician assessments. This makes AI-driven testing for lung conditions remarkably easy for pulmonologists. The company ensures clinicians gain new insights about their patients. These insights support more informed decision-making.
The strategic investments will fuel IMVARIA's growth trajectory. They will expand its reach and capabilities. The capital strengthens the company’s ability to develop new AI-based digital biomarker solutions. It reinforces the vision of leveraging AI for a significantly positive difference in patient care. This marks an important milestone in IMVARIA's emergence as a leading AI-powered test services partner.
IMVARIA is currently concentrating on non-invasive diagnoses for lung diseases. However, the company is actively exploring opportunities. It aims to expand its AI platform’s applications. These algorithms could support and accelerate the evolution of healthcare across broader areas. The long-term vision encompasses transforming chronic disease identification and treatment.
This investment reflects a shared vision. Investors and IMVARIA believe AI can dramatically improve patient care. This is achieved through fast and efficient diagnostics. Supporting innovative technologies like IMVARIA's helps shape the future of digital health. It makes healthcare more streamlined and effective for everyone involved. IMVARIA is poised to lead this charge.
IMVARIA, a prominent Berkeley, CA-based health tech company, has secured significant strategic investments. This funding will accelerate the expansion of its cutting-edge AI-driven diagnostic services. The capital injection targets various forms of lung disease. It ensures greater accessibility for clinicians, particularly pulmonologists. This move solidifies IMVARIA's position in the evolving digital health landscape.
The investment round saw InHealth Ventures take the lead. This early-stage fund is closely associated with InHealth Group, a leader in screening and diagnostics. Additional participation came from the Labcorp Venture Fund. Existing partner Cedar Crest Holdings also reinvested. Financial terms of the deal remain undisclosed. This strategic backing underscores confidence in IMVARIA's innovative approach to healthcare.
IMVARIA develops sophisticated AI-driven digital biomarker solutions. These tools empower clinicians. They facilitate earlier and more precise diagnoses and prognoses. The company’s AI platform leverages automated, machine-learning algorithm technology. It transforms complex clinical decision-making into data-driven science. This approach promises a paradigm shift in medical diagnostics.
The company's primary focus remains lung disease. This area presents significant diagnostic challenges. IMVARIA’s AI platform offers a new pathway for non-invasive diagnoses. It targets conditions like interstitial lung disease, including idiopathic pulmonary fibrosis. Early detection is critical for better patient outcomes. IMVARIA's technology aims to provide this crucial advantage.
Fibresolve stands as IMVARIA's flagship offering. This AI-powered test received FDA authorization in early 2024. Its use is authorized for suspected interstitial lung disease. Fibresolve employs a centralized model. It applies artificial intelligence to guide non-invasive diagnoses. The service integrates smoothly into existing clinical workflows. It minimizes the burden on healthcare providers.
Fibresolve also holds the esteemed FDA Breakthrough Device designation. This status highlights its potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases. Furthermore, the American Medical Association (AMA) has adopted CPT billing codes for Fibresolve. These codes simplify clinical ordering and reimbursement processes. They remove significant barriers to widespread adoption.
IMVARIA's commitment to innovation extends beyond existing solutions. The company recently secured a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). This grant supports the development of a new test. This test aims to improve malignancy assessment in chest CT scans. It builds upon IMVARIA’s robust existing lung disease platform. This expansion promises new capabilities in cancer detection.
The company was founded in 2019. Its founders are practicing physicians. They trained at Stanford School of Medicine. They also bring engineering expertise from Google. This unique blend of medical insight and technological prowess underpins IMVARIA's success. It has enabled the development of AI-powered tests with two FDA authorizations. This background fosters a deep understanding of clinical needs.
IMVARIA has established commercial traction. Its approach integrates AI seamlessly into clinical settings. The goal is to provide richer data sets for clinician assessments. This makes AI-driven testing for lung conditions remarkably easy for pulmonologists. The company ensures clinicians gain new insights about their patients. These insights support more informed decision-making.
The strategic investments will fuel IMVARIA's growth trajectory. They will expand its reach and capabilities. The capital strengthens the company’s ability to develop new AI-based digital biomarker solutions. It reinforces the vision of leveraging AI for a significantly positive difference in patient care. This marks an important milestone in IMVARIA's emergence as a leading AI-powered test services partner.
IMVARIA is currently concentrating on non-invasive diagnoses for lung diseases. However, the company is actively exploring opportunities. It aims to expand its AI platform’s applications. These algorithms could support and accelerate the evolution of healthcare across broader areas. The long-term vision encompasses transforming chronic disease identification and treatment.
This investment reflects a shared vision. Investors and IMVARIA believe AI can dramatically improve patient care. This is achieved through fast and efficient diagnostics. Supporting innovative technologies like IMVARIA's helps shape the future of digital health. It makes healthcare more streamlined and effective for everyone involved. IMVARIA is poised to lead this charge.